



PHARMACOGENOMICS TEST TO BETTER TREAT PATIENTS

**[50
Genes]**

PGxOne™ Plus is a pharmacogenomics test that can help predict how a patient will respond to drug therapy based on individual genetic makeup.

- Genetic variants affect drug absorption, metabolism and activity. Results guide effective treatment decisions, potentially reducing adverse drug events (ADEs) and trial-and-error drug selection and dosing.
- Provides recommendations for over 300 commercial drugs, with extensive coverage of psychiatric, cardiac and pain medications
- Cutting-edge Next Generation Sequencing (NGS) technology enables comprehensive coverage of ~200 genetic variants in 50 genes.
- Delivers medically actionable recommendations in an easy to interpret report.

Selected Covered Drug Classes from Major Therapeutic Areas

Cardiology

ACE Inhibitors
 Angiotensin II Receptor Blockers (ARBs)
 Antianginal Agent
 Antiarrhythmic Agent
 Anticoagulant
 Antiplatelet
 Beta Blockers
 Calcium Channel Blockers
 Diuretics
 Phosphodiesterase Inhibitors
 Antilipemic Agent(statins)
 Vasodilators

Psychiatry

Aldehyde Dehydrogenase Inhibitors
 Antianxiety Agents
 Antidepressants
 Antimanic Agents
 Antipsychotics
 Benzodiazepines
 Tricyclic Antidepressants
 Cannabinoids
 SNRIs
 SSRIs
 Stimulants

Pain Management

Anesthetics
 Central α -2 Adrenergic Agonists
 Alpha2-Adrenergic Agonist
 NSAIDs
 Opioids
 Opioids Antagonists
 Serotonin Receptor Agonists
 Skeletal Muscle Relaxant

Infectious Diseases

Antibiotics
 Antimalarial Drugs
 Antiviral Drugs
 Protease Inhibitors

Neurology

Anticonvulsant Drugs
 Barbiturates
 COMT Inhibitors
 Monoamine Depletors
 Antimigraine Agent

Oncology

Taxane Derivative
 Antimetabolite
 Platinum Analog
 Alkylating Agent
 Anthracycline
 Chemotherapy Modulating Agent
 Urate-Oxidase
 Estrogen Receptor Modulator
 Kinase Inhibitor
 Antiemetic Topoisomerase Inhibitors
 Immunomodulators
 Vinca Alkaloids

Associated drugs carry pharmacogenomics recommendations put forth by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and/or related pharmacogenomics publications.

